Mark A. Exley

机构：Bioscience Research, PaxVax (United States) · ORCID：0000-0002-5088-1032

发表论文 225 篇 · 总被引 12807 次 · h-index 59

代表论文

• A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome (2024 · Nature Communications · 被引 39)
• CAR-iNKT cells: redefining the frontiers of cellular immunotherapy (2025 · Frontiers in Immunology · 被引 14)
• Innate iNKT cells: from biological insight to clinical impact (2025 · Frontiers in Immunology · 被引 11)
• Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy (2023 · Journal of Neuro-Oncology · 被引 4)
• The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity (2025 · Cancer Immunology Research · 被引 2)
• 645 IMANs: a transformative allogeneic neutrophil cell therapy for rejuvenating innate immunity and overcoming treatment resistance in solid tumours (2025 · Regular and Young Investigator Award Abstracts · 被引 1)